Welcome to the UPF Digital Repository

The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain



The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

Thumbnail
Document Type: Article
Version: Published version
Date: 2021
This document is associated with a Creative Common license © 2020 Pfizer SLU. Mycoses published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Thumbnail

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking